[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369673-105":59,"doc-detail-369673-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-immunotherapy-and-targeted-therapy-for-advanced-clear-cell-renal-cell-carcinoma-current-strategies-and-future-directions-review","Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions - review","","Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma analyzes how modern systemic treatments reshape management of ccRCC, a dominant renal cancer subtype marked by substantial genetic and biological heterogeneity. Surgical resection alone cannot prevent high recurrence risk, creating an unmet need for effective adjuvant strategies. The review describes immune checkpoint inhibitors that enhance antitumor immunity and targeted agents, including TKIs and mTOR inhibitors, that interfere with angiogenesis and proliferation signaling. It also outlines limitations and directions for future research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-immunotherapy-and-targeted-therapy-for-advanced-clear-cell-renal-cell-carcinoma-current-strategies-and-future-directions-review/369673/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-immunotherapy-and-targeted-therapy-for-advanced-clear-cell-renal-cell-carcinoma-current-strategies-and-future-directions-review/369673.png","ImageObject",300,407,{"name":92,"@type":93},"Cipher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why does the review focus on clear-cell renal cell carcinoma (ccRCC)?","Question",{"text":112,"@type":113},"ccRCC accounts for most kidney cancers and is the most studied subtype clinically, while non-clear cell RCC remains understudied because of its rarity and limited trial inclusion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What treatments does the review consider under immunotherapy?",{"text":117,"@type":113},"It discusses immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 antagonists that enhance antitumor immune responses.",{"name":119,"@type":110,"acceptedAnswer":120},"How do targeted therapies work in the context of ccRCC?",{"text":121,"@type":113},"The review highlights agents like TKIs and mTOR inhibitors that disrupt angiogenesis and proliferation signaling pathways relevant to tumor progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369673,1790313573,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Review  \nPUBLISHED 03 July 2025  \nDOI 10.3389/fimmu.2025.1582887  \nOPEN ACCESS  \nEDITED BY  \nMeng Zhang,  \nFirst Afﬁliated Hospital of Anhui Medical University, China  \nREVIEWED BY  \nKarthik Dhatchinamoorthy,  \nUniversity of Massachusetts Medical School, United States  \nSawkar Vijay Pramod,  \nPadjadjaran University, Indonesia  \n*CORRESPONDENCE  \nBo Wang  \n [bowang581@gmail.com](bowang581@gmail.com)[ ](bowang581@gmail.com)Jiajia Ma  \n[jiajia.ma@uniklinik-freiburg.de](jiajia.ma@uniklinik-freiburg.de)  \n†These authors have contributed equally to this work  \nRECEIVED 25 February 2025  \nACCEPTED 06 June 2025  \nPUBLISHED 03 July 2025  \nCITATION  \nWang B, Xiang Y, Liu X, Pan X, Peng L and Ma J (2025) Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.  \nFront. Immunol. 16:1582887 .  \ndoi: 10.3389/fimmu.2025.1582887  \nCOPYRIGHT  \n© 2025 Wang, Xiang, Liu, Pan, Peng and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma:  \ncurrent strategies and future directions  \nBo Wang 1*†, Yuchu Xiang 2,3, Xudong Liu 1, Xiaoting Pan 4, Lang Peng 1 and Jiajia Ma 1*†  \n1 Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2 Department of Dermatology, West China Hospital, Sichuan University, Chengdu, China, 3 Laboratory of Dermatology, Clinical Institute of Inﬂammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China, 4 Department of Clinical Medicine, Shanghai Medical College, Fudan University, Shanghai, China  \nRenal cell carcinoma (RCC), particularly the clear-cell subtype (ccRCC), accounts for 75-85% of kidney cancers and exhibits distinct genetic and biological heterogeneity. While surgical resection remains the mainstay of treatment for localized ccRCC, the persistence of recurrence rates underscores the signiﬁcantunmet need for effective adjuvant therapies. Recent advancements in immunotherapy and targeted therapies have revolutionized the management of RCC. Immune checkpoint inhibitors have signiﬁcantly enhanced antitumor immune responses, whereas tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors effectively disrupt angiogenesis and proliferation signaling pathways, respectively. However, non-clear cell RCC subtypes remain understudied due to their rarity and exclusion from major clinical trials. Consequently, this review primarily focuses on ccRCC, aiming to provide a comprehensive and up-to-date overview of the latest advancements in immunotherapy and targeted therapies. By synthesizing current evidence, this review seeks to elucidate the mechanisms of action, clinical efﬁcacy, and limitations of these treatments, while also identifying gaps in knowledge and future research directions. Ultimately, the goal is to offer valuable insights for clinicians and researchers, facilitating the development of optimized, personalized treatment approaches to improve outcomes for ccRCC patients.  \nKEYWORDS  \nrenal cell carcinoma, immunotherapy, targeted therapy, current strategies, future directions  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nRenal cancer remains a common cancer globally, with an estimated 431,288 new cases in 2020 worldwide (1) . Recent studies suggest that new favorable subsets of cancers of unknown primary (CUP), including renal cell carcinoma (","cbCaiuaj94CEHCgm","https://ap.wps.com/l/cbCaiuaj94CEHCgm","pdf",3637567,25,"English","# Introduction\n## Rationale for adjuvant therapies in ccRCC\n## Role of immunotherapy and targeted therapy","[{\"question\":\"Why does the review focus on clear-cell renal cell carcinoma (ccRCC)?\",\"answer\":\"ccRCC accounts for most kidney cancers and is the most studied subtype clinically, while non-clear cell RCC remains understudied because of its rarity and limited trial inclusion.\"},{\"question\":\"What treatments does the review consider under immunotherapy?\",\"answer\":\"It discusses immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 antagonists that enhance antitumor immune responses.\"},{\"question\":\"How do targeted therapies work in the context of ccRCC?\",\"answer\":\"The review highlights agents like TKIs and mTOR inhibitors that disrupt angiogenesis and proliferation signaling pathways relevant to tumor progression.\"}]","Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions - review | PDF",1790184048,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05bb6dcfbee3fa3ab7dfb8a83357c75f.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af50a76d45660d5113e11e3f78553419.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/392ab4c79f852a7a7204c9de7257f761.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4e0d7a67d40a85c904e4c8af8ab2976.webp",980,1385]